142 related articles for article (PubMed ID: 6338971)
1. Comparative evaluation of fifteen anti-sickling agents.
Chang H; Ewert SM; Bookchin RM; Nagel RL
Blood; 1983 Apr; 61(4):693-704. PubMed ID: 6338971
[TBL] [Abstract][Full Text] [Related]
2. Influence of pH on the rheologic and antisickling effects of dimethyl adipimidate.
Pennathur-Das R; Lande WM; Mentzer WC; Mohandas N; Preisler H; Kleman KM; Heath RH; Lubin BH
J Lab Clin Med; 1984 Nov; 104(5):718-29. PubMed ID: 6491469
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of sickling.
Mentzer WC
Am J Pediatr Hematol Oncol; 1982; 4(3):320-7. PubMed ID: 7149171
[TBL] [Abstract][Full Text] [Related]
4. New Approaches to the therapy of sickle cell disease.
Luskey KL; Schechter AN; Hercules JI
Tex Rep Biol Med; 1980-1981; 40():305-12. PubMed ID: 6172868
[No Abstract] [Full Text] [Related]
5. Advances in the understanding of sickle cell anemia.
Charache S
Hosp Pract (Off Ed); 1986 Feb; 21(2):173-8, 182-90. PubMed ID: 2419352
[No Abstract] [Full Text] [Related]
6. Effects of cetiedil on monovalent cation permeability in the erythrocyte: an explanation for the efficacy of cetiedil in the treatment of sickle cell anemia.
Berkowitz LR; Orringer EP
Blood Cells; 1982; 8(2):283-8. PubMed ID: 7159752
[TBL] [Abstract][Full Text] [Related]
7. 5'-deoxypyridoxal as a potential anti-sickling agent.
Benesch R; Benesch RE; Edalji R; Suzuki T
Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1721-3. PubMed ID: 266212
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of erythrocyte sickling in vitro by pyridoxal.
Kark JA; Kale MP; Tarassoff PG; Woods M; Lessin LS
J Clin Invest; 1978 Oct; 62(4):888-91. PubMed ID: 701485
[TBL] [Abstract][Full Text] [Related]
9. Survival rates and properties of sickle cell anemia red cells treated with nitrogen mustard.
Roth EF; Wenz B; Lee HB; Fabry M; Chang H; Kaul DK; Baez S; Nagel RL
Prog Clin Biol Res; 1987; 240():245-61. PubMed ID: 3615491
[TBL] [Abstract][Full Text] [Related]
10. The mechanism of action of two anti-sickling agents: sodium cyanate and glyceraldehyde.
Manning JM; Acharya AS
Am J Pediatr Hematol Oncol; 1984; 6(1):51-4. PubMed ID: 6711764
[TBL] [Abstract][Full Text] [Related]
11. Understanding antisickling agents and the sickling process.
Godwin M; Baysinger M
Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864
[No Abstract] [Full Text] [Related]
12. Structural features required for the reactivity and intracellular transport of bis(3,5-dibromosalicyl)fumarate and related anti-sickling compounds that modify hemoglobin S at the 2,3-diphosphoglycerate binding site.
Chatterjee R; Iwai Y; Walder RY; Walder JA
J Biol Chem; 1984 Dec; 259(23):14863-73. PubMed ID: 6501320
[TBL] [Abstract][Full Text] [Related]
13. A view of the current status of antisickling therapy.
Brewer GJ
Am J Hematol; 1976; 1(1):121-8. PubMed ID: 790948
[No Abstract] [Full Text] [Related]
14. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
Oder E; Safo MK; Abdulmalik O; Kato GJ
Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
[TBL] [Abstract][Full Text] [Related]
15. In vitro effects of anthocyanin extracts from Justicia secunda Vahl on the solubility of haemoglobin S and membrane stability of sickle erythrocytes.
Mpiana PT; Ngbolua KN; Bokota MT; Kasonga TK; Atibu EK; Tshibangu DS; Mudogo V
Blood Transfus; 2010 Oct; 8(4):248-54. PubMed ID: 20967165
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of covalent antisickling compounds by PO2 scan ektacytometry.
Johnson RM; Féo CJ; Nossal M; Dobo I
Blood; 1985 Aug; 66(2):432-8. PubMed ID: 4016278
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.
Safo MK; Kato GJ
Hematol Oncol Clin North Am; 2014 Apr; 28(2):217-31. PubMed ID: 24589263
[TBL] [Abstract][Full Text] [Related]
18. Urea, cyanate and sickling.
Harris A
N Engl J Med; 1971 Sep; 285(12):690-1. PubMed ID: 5563487
[No Abstract] [Full Text] [Related]
19. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.
Omar AM; Abdulmalik O; Ghatge MS; Muhammad YA; Paredes SD; El-Araby ME; Safo MK
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33147875
[TBL] [Abstract][Full Text] [Related]
20. Diaspirins that cross-link beta chains of hemoglobin: bis(3,5-dibromosalicyl) succinate and bis(3,5-dibromosalicyl) fumarate.
Walder JA; Zaugg RH; Walder RY; Steele JM; Klotz IM
Biochemistry; 1979 Oct; 18(20):4265-70. PubMed ID: 486423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
